Indicated for: chronic hepatitis C
Substance: daclatasvir (antiviral)
ATC: J05AX14 (Antiinfectives for systemic use | Direct acting antivirals | Other antivirals)
Daclatasvirum is an antiviral medication used for the treatment of chronic hepatitis C. It works by inhibiting the NS5A protein, which is essential for the replication of the hepatitis C virus, thereby helping to eliminate the infection.
The medication is taken orally, usually in combination with other antivirals such as sofosbuvir, to enhance treatment effectiveness. It is indicated for various genotypes of the hepatitis C virus.
Side effects may include fatigue, headache, nausea, and insomnia. In rare cases, allergic reactions or other severe side effects may occur. It is important to follow all medical recommendations during treatment.
Consult your doctor to discuss the benefits and risks of treatment with Daclatasvirum. Regular monitoring is essential to ensure the success of the therapy.